IL-33 in COVID-19: friend or foe?
Cell Mol Immunol
.
2021 Jun;18(6):1602-1604.
doi: 10.1038/s41423-021-00685-w.
Epub 2021 May 10.
Authors
Yuejin Liang
#
1
2
,
Yiyue Ge
#
3
,
Jiaren Sun
4
5
Affiliations
1
Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA. yu2liang@utmb.edu.
2
Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA. yu2liang@utmb.edu.
3
NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
4
Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA. jisun@utmb.edu.
5
Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA. jisun@utmb.edu.
#
Contributed equally.
PMID:
33972738
PMCID:
PMC8108013
DOI:
10.1038/s41423-021-00685-w
No abstract available
Publication types
Research Support, N.I.H., Extramural
MeSH terms
COVID-19 / immunology*
Cell Line
Humans
Interleukin-33 / immunology*
SARS-CoV-2 / immunology*
Substances
IL33 protein, human
Interleukin-33
Grants and funding
R01 EY028773/EY/NEI NIH HHS/United States
R21 AI153586/AI/NIAID NIH HHS/United States
AI153586/U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
EY028773/U.S. Department of Health & Human Services | NIH | National Eye Institute (NEI)